Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION

FDA ADVISORY
No. 20201563

18 AUG 2020

TO : **THE GENERAL CONSUMING PUBLIC**

SUBJECT : **Public Health Warning Against the Purchase and Use of Adulterated, Misbranded, and Unregistered Health Product "Ethyl Alcohol 70% Solution 500 mL"**

The Food and Drug Administration (FDA) warns the public against the purchase and use of adulterated, misbranded, and unregistered health product which poses potential danger or injury to health:

PRODUCT IMAGE

Ethyl Alcohol 70% Solution 500 mL

Figure 1. Adulterated, Misbranded, and Unregistered Health Product

FDA Post-Marketing Surveillance (PMS) activities has verified that the abovementioned health product has not gone through the registration process of the Agency and not been issued with proper market authorization, e.g., Certificate of Product Registration.

The FDA laboratory analysis showed that the product does not contain Ethyl Alcohol, as labeled, but instead has 32.94% Isopropyl Alcohol.

In light of the foregoing, the public is advised to always check if a health product has been registered with the FDA before purchasing it by making use of the embedded Search feature at the FDA website (**www.fda.gov.ph**). You may also look for the FDA Registration number on the product label.

All concerned establishments and/or entities are warned not to manufacture, distribute, sell, or offer for sale the adulterated/misbranded/unregistered health product. Pursuant to Section 11, subsections (a) and (b) of Republic Act No. 9711, otherwise known as the "Food and Drug Administration Act of 2009", the following acts and the causing thereof: (a) the manufacture, importation, exportation, sale, offering for sale, distribution, transfer, non-consumer use, promotion, advertising, or sponsorship of any health product that is adulterated, unregistered or misbranded; and (b) the adulteration or misbranding of any health product are prohibited.

All Law Enforcement Agencies (LEAs) and Local Government Units (LGUs), are requested to ensure that this product is not sold or made available in their localities or areas of jurisdiction.

For more information or inquiries, please e-mail us at cdrr_postmarketsurveillance@fda.gov.ph. To report any sale or distribution of the abovementioned, kindly e-mail us via ereport@fda.gov.ph. You may also call the Center for Drug Regulation and Research (CDRR) at telephone number **(02) 8809-5596**. Any suspected adverse reaction experienced from the use of the product should be reported immediately to the FDA through this link: https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH and fill-out all of the required fields.

Dissemination of this advisory to all concerned is hereby requested.

ROLANDO ENRIQUE D. DOMINGO, MD
Director General

20200511153612